What did @realnickcalabrese actually say?
Nick walked through four compounds he's currently using: NAD+ at 50mg on Sundays for "overall energy" and anti-aging, MT-2 (melanotan II) at 250mcg to maintain a tan without sun exposure, tesamorelin at 1mg nightly on an empty stomach to "signal your body to produce more natural growth hormone" and burn visceral fat, and what sounds like CJC-1295 or a GHRH analog at 4mg weekly, which he calls "the king of kings" and describes as a "fat burning machine." He noted he hadn't tapered CJC since summer, which he acknowledges is slow progress.
He also gave practical protocol notes: fast for two hours before tesamorelin, dose MT-2 midday, and use the high CJC dose because he hasn't cycled off. Some of this is operationally specific in a way that signals personal experience rather than copy-paste advice.
Does the science back this up?
Tesamorelin is the most evidence-backed compound here by a wide margin. The rest range from moderately supported to genuinely concerning. MT-2 in particular sits in a different risk category than the others, and the framing of CJC at 4mg weekly deserves scrutiny.
Tesamorelin is FDA-approved (brand name Egrifta) specifically for HIV-associated lipodystrophy, where it demonstrably reduces visceral adipose tissue. Falutz et al. (2010, NEJM) showed significant VAT reduction in a phase 3 trial. That mechanism, stimulating endogenous GH release via GHRH receptor agonism, is real and well-characterized. The claim that it "signals your body to produce more natural growth hormone" is technically accurate.
NAD+ precursor supplementation has biological plausibility. Yoshino et al. (2021, Science) showed NMN improved insulin sensitivity in postmenopausal women. But oral NAD+ itself has poor bioavailability, and 50mg is a low dose compared to most studied protocols. The anti-aging claim is plausible in direction but oversimplified.
MT-2 has no approved clinical use anywhere. Studies on melanocortin receptor agonists exist, but MT-2 specifically carries documented cardiovascular and dermatological risks. Wessells et al. (2000, Journal of Urology) explored it for erectile dysfunction but noted significant adverse effects.
What did they get wrong (or right)?
Nick got tesamorelin's mechanism basically right. Crediting him for that matters because most social media peptide content gets GHRH versus GHRP confused or ignores the distinction entirely. The empty-stomach protocol is also consistent with how tesamorelin is used clinically to optimize GH pulse response.
Where things go sideways: MT-2 is not a benign tanning supplement. Describing it as something that helps "hold my base tan" understates the risk profile. Melanotan II is an unregulated, non-approved compound with documented cases of atypical moles, nausea, spontaneous erections, and cardiovascular events. The European Medicines Agency has issued multiple warnings. Using it to avoid sun exposure while still going to a tanning bed raises additional questions about the actual UV exposure being reduced.
The CJC dose of 4mg weekly is high. Standard research protocols for CJC-1295 with DAC typically use 1-2mg weekly. Nick's reasoning, that he hasn't tapered since summer, is at least honest, but self-dosing a GHRH analog at elevated doses without clinical monitoring for IGF-1 levels is not something to normalize in a 44K-view TikTok.
What should you actually know?
These are not equivalent compounds in terms of evidence or risk. Tesamorelin has a regulatory track record. The others do not, and that gap matters when you're injecting something purchased from a research chemical supplier.
A few things worth understanding before anyone considers this territory. First, "signals your body to produce more natural growth hormone" sounds gentle, but chronically elevated IGF-1 from GHRH analogs has theoretical cancer promotion risk, particularly with extended unsupervised use. Sandhu et al. (2002, Journal of the National Cancer Institute) found associations between elevated IGF-1 and colorectal cancer risk in prospective data. Second, NAD+ supplementation through precursors like NMN or NR is more bioavailable than oral NAD+ itself. 50mg of oral NAD+ on Sundays is unlikely to meaningfully raise NAD levels compared to daily NMN dosing studied in clinical trials. Third, MT-2's mechanism is promiscuous across melanocortin receptors, which explains both its tanning effect and its side effect profile. It is not a targeted cosmetic product. Fourth, any GHRH analog stack requires periodic IGF-1 testing to avoid sustained supraphysiologic exposure. That monitoring step is absent from this video entirely.
Bottom line
Nick clearly has hands-on experience with these compounds, and his tesamorelin commentary is more accurate than most. But the MT-2 framing is genuinely irresponsible, the CJC dose needs clinical context, and the overall presentation treats serious injectable peptides as a manageable supplement routine without flagging the monitoring that responsible use actually requires.